Investigating how IL-27 helps T cells fight tumors
IL-27 functions as a novel signal 3 cytokine and promotes cytotoxic T cell responses to tumors
This study is looking at how a substance called IL-27 can help boost the immune system's ability to fight tumors, with the hope that it will lead to better cancer treatments for patients like you.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Harvard Medical School NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11054771 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of IL-27, a cytokine, in enhancing the immune response of CD8+ T cells against tumors. By using a CRISPR-based screening platform, the researchers aim to identify the necessary signals that promote the effectiveness of these T cells in cancer therapy. The study will explore how manipulating IL-27 can improve the infiltration and activity of CD8+ T cells in tumors, potentially leading to better outcomes for cancer patients. Patients may benefit from insights gained about how to enhance their immune response to cancer treatments.
Who could benefit from this research
Good fit: Ideal candidates for this research are cancer patients who are not responding to current immunotherapy treatments.
Not a fit: Patients with cancers that do not involve CD8+ T cell responses may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer immunotherapies that significantly improve patient outcomes.
How similar studies have performed: Other research has shown promising results in enhancing T cell responses through cytokine manipulation, suggesting that this approach could be effective.
Where this research is happening
Boston, United States
- Harvard Medical School — Boston, United States (Active)
Researchers
- Principal investigator: Lafleur, Martin — Harvard Medical School
- Study coordinator: Lafleur, Martin
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.